Investment firm Bain Capital has completed its full exit from pharmaceutical company Emcure Pharmaceuticals through a ₹350 crore block deal, selling its remaining 1% stake for ₹350 crore at a floor price of ₹1,817 per share. According to Moneycontrol, the transaction was structured as a clean-out trade and executed by BC Investments IV on the day of the announcement. The exit marks the final chapter of a 12-year investment that began when Bain Capital acquired a 13% stake from global investment firm Blackstone in December 2013 for approximately ₹700 crore. Investment banks Kotak Mahindra Capital and Axis Capital reportedly acted as advisers on the transaction.
The final exit follows a series of strategic stake sales by Bain Capital since Emcure Pharma's successful stock market debut in July 2024. On April 30, 2026, the firm divested nearly a 1% stake through open market transactions, selling 18 lakh shares for over ₹289 crore. Earlier on June 9, 2026, BC Investments IV sold 36 lakh shares via a block deal at ₹1,700 per share, amounting to ₹612 crore. The latest block deal represents the culmination of this gradual reduction in ownership as the investment firm gradually reduced its holding in the company over the past few years.
The company delivered robust financial results for the quarter, with net profit rising 29% year-on-year to ₹243 crore from ₹189 crore. According to CNBC TV18, revenue increased 16.7% to ₹2,469.7 crore compared to ₹2,116.2 crore in the year-ago period, reflecting healthy traction across key markets. EBITDA grew 19.2% to ₹479.5 crore, while margins improved marginally to 19.4% from 19% a year earlier. The strong performance has coincided with significant investor interest, with Emcure Pharma's shares gaining more than 30% over the last six months following its public listing.
The company's international business remained the key growth driver, with sales rising 25.7% YoY to ₹1,493 crore, supported by base business ramp-up and new product launches. As reported by CNBC TV18, domestic sales came in at ₹977 crore, up 5.2% YoY, impacted by softer performance in the Zuventus portfolio and organisational restructuring. The board recommended a final dividend of ₹3.60 per share for FY26, subject to shareholder approval.
Shares of Emcure Pharmaceuticals have responded positively to the exit announcement, with the stock gaining more than 30% over the last six months following its public listing. According to Moneycontrol, the exit coincides with strong investor interest in the Pune-based pharmaceutical company. Even as it exits Emcure Pharma, Bain Capital continues to evaluate new opportunities in India, as reported by Outlook Business. The firm's exit from the pharmaceutical sector comes after Bain Capital and Canada Pension Plan Investment Board (CPPIB) were among investors competing in the final stage of a $500 million-$750 million fundraising process for integrated real assets platform RMZ Group.
